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Abstract
Introduction: Targeting antigens to dendritic cells (DCs) in vivo via a
DC-restricted endocytic receptor, DEC205, has been validated to enhance
immunity in several vaccine platforms. Particularly atttractive is selected delivery
of proteins to DCs in vivo because it enables proteins to bemore immunogenic and
provides a cheaper and effective way for repeated immunizations.
Methods: In this study, we tested the efﬁcacy of a single chain antibody to DEC205
(scDEC) to deliver protein antigens selectively to DCs in vivo and to induce
protective immunity.
Results: In comparison to soluble Ovalbumin (OVA) antigen, when recombinant
scDEC:OVA protein was injected subcutaneously (s.c.) intomice, the OVA protein
was selectively presented by DCs to both TCR transgenic CD8þ and CD4þ T cells
approximately 500 and 100 times more efﬁcient than soluble OVA, respectively,
and could persist for seven days following s.c. injection of the scDEC205:OVA.
Similarly selective targeting of HIV Gag P24 to DCs in vivo using scDEC-Gag
protein plus polyICLC vaccine resulted in strong, long lasting, polyfuntional CD4þ
T cells in mice which were protective against airway challenge by a recombinant
vaccinia-gag virus.
Conclusion: Thus targeting protein antigens to DCs using scDEC can be used
either alone or in combination with other strategies for effective immunization.
1© 2017 The Authors. Immunity, Inflammation and Disease Published by John Wiley & Sons Ltd.
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Introduction
Recombinant protein vaccines are attractive because they
enable immune responses to be focused on protective
antigens. Due to their potent ability to prime immune
responses, dendritic cells (DCs), loaded with antigen in
vitro and in vivo, are presently explored as vaccine
candidates against cancer and infectious diseases
(reviewed in [1–10]). Our group and others have
previously demonstrated that selective delivery of proteins
to DCs in vivo allowed proteins to be more immunogenic
and provided a cheaper and effective way for repeated
immunizations [11–23]. Our strategy involving targeting
antigens to DCs via antigens coupled to a monoclonal
antibody against a DC-restricted endocytic receptor,
DEC205, led to efﬁcient immunity [12–14, 23–33]. Here
we describe a simple and cheap approach of targeting
whole protein antigen to DCs in vivo, based on a single
chain antibody to DEC205 (scDEC) fused to a protein
antigen of interest. Due to its small size scDEC offers
several attractive capacities including rapid tissue pene-
tration, low cost of production and no Fc domain. The
absence of an Fc domain eliminates potential interaction
with Fc receptor-expressing cells thereby improving not
only speciﬁc targeting to DCs but also allowing for
repeated immunizations without inducing deleterious
host antibody responses [34–37]. In prior studies our
group and others have demonstrated the immunogenicity
of scDEC-targeted antigen after incorporation in both
DNA and viral vectored vaccines [25, 31, 38, 39]. Here we
prioritize scDEC-protein vaccines because they offer a
unique opportunity for scaling up strategies optimized
with the parental anti-DEC205 monoclonal antibody
(aDECmAb)-protein vaccines for eventual application
in underdeveloped countries. Since scDEC might improve
pharmacokinetics by eliminating rapid clearance of
immunogen by Fc receptors, there is need to compare
scDEC and aDECmAb to determine vaccine delivery
efﬁciencies. We found out that small amounts of puriﬁed
scDEC-OVA, when injected subcutaneously (s.c.) into
mice, could target OVA efﬁciently to DCs leading to both
MHC class I and II presentation in vivo. In comparison to
soluble OVA, injection of scDEC-OVA protein increased
in vivo presentation of antigenic peptides to MHC-I and
MHC-II-restricted T-cells by at least a factor of 250
and 20, respectively. This presentation persisted for seven
days as against 15 days when mice were similarly treated
with the parental aDECmAb-OVA protein. On the other
hand s.c. injection of scDEC-Gag in combination with
polyICLC resulted in robust HIV Gag speciﬁc polyfunc-
tional CD4þ T Cells which were protective to airway
challenge by recombinant vaccinia-gag virus. As such
scDEC-protein vaccines can be used either alone or in
combination with other strategies for effective
immunization.
Materials and Methods
Cell lines, media, and antibodies
The generation of CHO-neo and CHO-mDEC-205 cell lines
was described previously [13]. Antibodies to TCR speciﬁc-
ities (Vß5.1/5.2/MR9-4; Va2/20.1) and other cell surface
markers CD11c, CD8a, and CD4 were purchased from BD
Biosciences. Magnetic microbeads were from Miltenyi
Biotec. Other antibodies included rabbit aOvalbumin
(Chemicon, EMD Millipore, USA), mouse anti-c-Myc,
mouse anti-GFP, goat antirabbit-FITC and goat antimouse-
FITC (Biosource International, Inc, USA), and KC57FITC
(FITC-aP24, Coulter).
Vector construction
All vectors generated and used in this work have previously
been described in Ref. [30].
scDEC-fusion protein purification from the
supernatants of stably transfected CHO cells
The scDEC-OVA, scCont-OVA, scDEC-Gag, and
scCont-Gag fusion proteins were puriﬁed from the super-
natants of stably transfected CHO cells using Ni-NTA
agarose (Qiagen, Valencia, USA) through batch puriﬁcation
protocol according to the manufacturer’s instructions. The
puriﬁed proteins were concentrated by spin columns (EMD
Millipore, MA, USA) and dialysed overnight against PBS.
Protein concentration was estimated using the BCA Protein
Assay Kit according to manufacturer’s instructions (Life-
technology, USA).
SDS–PAGE and immunoblot analysis
The puriﬁed supernatants were resolved on 10% SDS–PAGE
under reducing conditions and either directly Coomassie
stained or blotted onto nitrocellulos (Amersham) by standard
techniques. The blotted protein was blocked with Roti-Block
(Rott) and then reacted with either rabbit anti-ovalbumin
polyclonal antibody (1:10000, Chemicon) followed by anti-
rabbit peroxidase conjugate (1:2000). Bands were visualized
with ECL substrate (Amersham). For the detection of HIV
Gag p24 puriﬁed protein was resolved on a 10% SDS–PAGE
and treated similarly except that that HRP-conjugated
anti-p24 mAb was used for direct detection after blotting.
Mice
C57BL/6(B6), TAP/, DEK/, OT-I, OT-II, and the
CD45.1þ OT-I mice were obtained from Charles Rivers and
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maintained under standard conditions in the Rockefeller
University Animal Facility. All animals were used between 6
and 10 weeks under the guidelines of the Rockefeller
University Institutional Animal Care and Use Committee.
All necessary ethical approvals has been also acquired from
the participating institutions.
In vivo capture of scDEC205-OVA fusion protein
B6 mice were injected subcutaneously in the four paws with
5mg of scDEC-OVA fusionproteins. Lymphnodes (popliteal,
inguinal, axillary, branchial mesenteric) and spleen were
harvested 24 h later and DCs isolated. Brieﬂy single cell
suspensions were prepared with 400U/ml collagenase
(Roche) for 25min at 378C. The cells were then incubated
with anti-mouse CD11c microbeads for 30min at 378C.
CD11cþ (DC-enriched) and negative cells were separated by
application of a magnetic ﬁeld. CD8þ or CD4þ T cells were
prepared from OT-I or OT-II mice, respectively. OT-I and
OT-II T cells were puriﬁed from single cell suspensions of
lymph node or spleen cells by negative selection using
hybridoma supernatants directed against MHC-II, F4/80,
B220, NK1.1, andCD4 orCD8 and goat anti-rat Dynabeads1
(Dynal, Thermo Fisher Scientiﬁc, USA) at a ratio of 4 beads to
1 target cell. Culture medium was RPMI, 7% FBS, 100U/ml
penicillin streptomycin mixture, 0.25mg/ml fungizone,
10mM Hepes, and 55mM ß-mercaptoethanol.
Labeling of cells with CFSE for in vivo T cells
proliferation responses
CD8þ or CD4þ T cells were prepared from OT-I or OT-II
mice respectively. OT-I and OT-II T cells were puriﬁed from
single cell suspensions of lymph node or spleen cells by
negative selection using hybridoma supernatants directed
against MHC-II, F4/80, B220, NK1.1, and CD4 or CD8 and
goat anti-rat Dynabeads1 (Dynal) at a ratio of 4 beads to 1
target cell. OT-I and OT-II cells at 107 cells/ml were
incubated with CFSE (Molecular probes; 5mM) for
10min at 378C. An equal volume of FCS was added, and
the cells washed two times with PBS/0.1% BSA and twice
with PBS. 2 106 labelled OT-I and 3 106 labelled OT-II
cells were injected intravenously into B6 recipients respec-
tively. 24 h later scfv:OVA fusion proteins were injected into
all 4 paws. After 3 days, both draining lymph nodes and
spleen cells were stained separately for Vß5.1/5.2, CD8 (OT-I),
Va2, CD4 (OT-II) and evaluated by multicolour ﬂow
cytometry.
Flow cytometry
Multicolor ﬂow cytometry was used to monitor in vivo
functional responses by analysing the proliferation of
carboxyﬂourescein diacetate succinimidyl ester (CFSE)-
labelled T cells as assed by progressive halving of the
amount of ﬂourescein per cell. We used a FACScaliburTM
(BD Biosciences, USA) with subsequent analysis of data in
CELLQuestTM (BD Biosciences) or FlowjoR (Tree Star, OR,
USA). Multiparametric ﬂowcytometry for HIV Gag speciﬁc
T cell responses was carried out as previously reported in our
group [25, 30, 31].
In vitro presentation of OVA by DCs
B6 mice were injected with 5 ug of scDEC205: OVA fusion
proteins subcutaneously in the 4 paws. Lymph nodes
(popliteal, inguinal, axillary, branchial mesenteric) and
spleen were harvested 24 h later and DCs isolated. Brieﬂy
single cell suspensions were prepared with 400U/ml
collagenase (Roche) for 25min at 378C. The cells were
then incubated with anti-mouse CD11c microbeads for
30min at 378C. CD11cþ (DC-enriched) and negative cells
were separated by application of a magnetic ﬁeld. CD8þ or
CD4þ T cells were prepared from OT-I or OT-II mice
respectively as described previously. Culture medium was
RPMI, 7% FBS, 100U/ml penicillin streptomycin mixture,
0.25mg/ml fungizone, 10mM Hepes, and 55 uM
ß-mercaptoethanol.
Assays for HIV-specific immune T cells
Female C57/B6 mice were injected twice i.p. at 4 weeks
interval with scDEC- or scCont-fusion protein together
with polyICLC (50mg, oncovir) as adjuvant. Fourteen days
following the last vaccination spleens were dissociated and
HIV gag-speciﬁc CD3þ CD4þ splenic T cells were analyzed
for simultaneous production of IFNg, IL-2, and TNF-a.
To determine the breadth of HIV Gag-speciﬁc T cell
responses, splenocytes were restimulated in vitro with
peptides mix spanning the entire Gag p24 protein
[25, 26, 29–31] or a negative unreactive control peptide
mix consisting of HIV Gag p17 pool 1 or HA in the
presence of 2 ug/ml of anti-CD28 (clone 37.51) for 6 h,
adding 10mg/ml brefeldin A (Sigma–Aldrich) for the last
4 h to accumulate intracellular cytokines. Dead cells were
excluded using live/dead ﬁxable dead stain kit (Aqua live/
dead; Thermo Fischer Scientiﬁc). After blocking FcyR
receptors, the cells were stained with antibodies to
CD3-paciﬁc blue, CD4-percp, CD8-alexa-750, and Aqua
live/dead stain for 20min at 378C. Cells were washed, ﬁxed
(Cytoﬁx/cytoperm; BD Bioscience), permeabilized with
Permwash and stained with antibodies to IFNg
(IFNg-alexa-700), IL-2 (IL-2-FITC), and TNF-a
(TNF-a-PE-CY7) for 15min at room temperature. All
antibodies were from Ebioscience. We use BD LSRII for
acquisition and data analysis was with Flowjo (Tree Star).
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Vaccinia-gag protection assay
Nembutal-anesthetized mice were challenged with
105 PFU/mouse of infectious recombinant vaccinia-gag
virus by the intranasal route, in 35ml PBS with Mg/Ca. A
negative control was vaccinia-OVA virus. The weight of each
animal (groups of 5) was determined daily for 6 days
following challenge. Then mice were euthanized, the lungs
were harvested and homogenized in transport medium
(0.1% gelatin in PBS), and stored in duplicates at 808C
prior to virus titration. Lung virus titers of individualmice in
each group were determined by plaque assay on monolayers
of CV-1 cells as described [24, 25, 29–31].
Statistics
Postchallenge mean vaccinia lung virus titers and mean
percentage in weight loss were compared between vaccina-
tion groups using one tailed Student’s t test. Differences were
considered signiﬁcant at P< 0.05 after analysis using prism 6
Graph Pad Software.
Results
In vivo targeting and presentation of antigen to
CD8þ T cells using scDEC-OVA
The parental aDECmAb has previously been demonstrated
to target protein efﬁciently to DCs leading to efﬁcient
presentation of antigens to both MHC classes I and II
pathways [11, 12, 33]. To verify that DCs targeted with the
scDEC-OVA could present antigens in situ, we performed
adoptive transfer of OVA-speciﬁc TCR transgenic T cells
(CD8þMHC class I-restricted OT-I) labeled with CFSE one
day before the injection of scDEC-OVA, scCont-OVA, or
soluble OVA. After 3 days, the draining lymph nodes
(Fig. 1A–C) and spleen (Fig. 1D–F) were evaluated for T cell
proliferation as assayed by CFSE dilution. Virtually all of the
OT-I cells in the draining lymph nodes and spleen entered
cell cycle and underwent several rounds of cell divisions with
a dose of just 100 ng of the scDEC-OVA (Fig. 1B and E). In
contrast, soluble OVA required the dose containing
approximately 500-fold more protein (250 ug OVA versus
0.5 ug scDEC-OVA) to induce comparable proliferative
responses and again scCont-OVA elicited little or no
proliferation (Fig. 1A and D). To determine whether
MHC class I presentation by scDEC-OVA was TAP
dependent, we performed similar experiments with
TAP-deﬁcient mice (TAP/, Fig. 1C and F). In the absence
of TAP, proteasome-processed peptides in DCs apparently
failed to move into the endoplasmic reticulum for
association with MHC class I after uptake of scDEC-OVA,
but the same cells were able to present OVA onMHC class II
(compare Fig. 1C and E with Fig. 2C and E). To prove that
DEC-205 but not Fcg receptors were mediating uptake and
presentation of antigens, we veriﬁed that CFSE dilution was
abolished when similar experiments were performed in
DEC-205 deﬁcient mice (DEC-205/, Fig. 1C and F).
In vivo targeting and presentation of antigen to
CD4þ T cells using scDEC-OVA
Similar adoptive transfer of CD4þ MHC class II-restricted
OT-II Transgenic T cells followed by subsequent injection of
scDEC-OVA revealed strong presentation of antigen to
OT-II T-cells (Fig. 2). Thus recombinant scDEC-OVA
efﬁciently targets antigens to DCs leading to presentation by
bothMHC class I andMHC class II pathways in vivo. Brieﬂy
mice were similarly treated as described above then 3 days
later, the draining lymph nodes (Fig. 2A–C) and spleen
(Fig. 2D–F) were evaluated for T cell proliferation as assayed
by CFSE dilution. Most but not all of the OT-II cells in the
draining lymph nodes (Fig. 2A–C) and spleen (Fig. 2D–F)
entered cell cycle and underwent several rounds of cell
divisions. However, for OT-II cells, a dose of at least 100 ng
of scDEC-OVA was necessary to initiate proliferation in the
draining lymph nodes (Fig. 2B). The minimal dose required
for scDEC-OVA presentation to OT-II cells in the spleen was
much higher, that is at least 500 ng (Fig. 2E). For soluble
OVA, approximately 100 fold more protein (250 ug OVA
versus 2.5 ug scDEC-OVA) was required to induce compa-
rable responses of OT-II T cell proliferation and, again,
scCont-OVA elicited little or no proliferation (Fig. 2A
and D). Since MHC class II presentation is independent of
TAP when similar experiments were performed in
TAP-deﬁcient mice (TAP/, Fig. 2C and F) OVA
presentation to OT-II T cells was not abrogated. To prove
that DEC205 but not Fcg receptors were mediating OT-II
presentation, we veriﬁed that CFSE dilution was abolished
when similar experiments were performed in DEC205
deﬁcient mice (DEC-205/, Fig. 2C and F).
Comparison between aDECmAb-OVA and
scDEC-OVA
When compared to OVA fused to recombinant aDECmAb
(parental antibody), targeting of DEC205 by the single
chain scDEC-OVA was comparable to the recombinant
aDECmAb-OVA except that higher doses (>50 ng) of
scDEC-OVA were required (Fig. 3 compare A and B). At
doses less than 100 ng, scDEC-OVA was comparatively less
efﬁcient. Following s.c. injection of scDEC-OVA, the antigen
presentation to TCR transgenic CD8þT cells persisted for up
to 7 days for the scDEC targeted proteins as compared to
15 days for the recombinant aDECmAb-OVA (compare
Fig. 3C and E with D and F). The aDEC monoclonal
antibody (aDECmAb) has previously been demonstrated to
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efﬁciently target antigens to CD11cþ DCs [11, 33, 34]. To
determine whether DCs could actually be targeted by
recombinant scDEC-OVA protein in vitro, CD11cþ and
CD11c cells were isolated from the draining lymph nodes
and spleen of na€vemice and co-cultured with OT-I T-cells in
1mg/ml of scDEC-OVA before measuring the proliferation
of T cells by uptake of [3H] thymidine at 48–78 h. We
detected strong presentation by the CD11cþ and not by the
CD11c cells (Fig. S1A). To verify that the scDEC-OVA
targeted DCs would be responsible for the antigen
presentation in vivo, we next isolated CD11Cþ and
CD11C cells from mice injected subcutaneously with the
scDEC-OVA or aDECmAb-OVA as positive control (data
not shown). When assayed for antigen presentation to
OT-I T cells in vitro at 24 h after injection of scDEC-OVA,
we could detect antigen presentation efﬁciently by the
CD11Cþ but not by the CD11C cells (Fig. S1B). Therefore
the scDEC-OVA could efﬁciently target OVA to DCs in vitro
and in vivo leading to antigen presentation.
scDEC-Gag protein vaccine in combination with
polyICLC induces robust durable polyfunctional
Gag specific CD4þ T cell responses
Effective HIV Gag speciﬁc T cell responses are vital in the
control of viremia and could be a useful component of
Figure 1. Antigen presentation to OT-I T cells following scDEC targeting in vivo. scDEC-OVA induces stronger in vivo proliferation of OT-I T cells than
OVA alone. C57BL/B6 mice were injected intravenously with 2 106 CFSE-labelled OT-I T-cells then graded doses of scDEC-OVA (A) or OVA (B)
subcutaneously 24 h later. Three days after scDEC injection, draining lymph node cells were harvested and the expansion of CD8þ Va2ß5.1/5.2 evaluated
by ﬂow cytometry for CFSE dilution. scDEC-OVA elicited better presentation of OVAderived peptide than the scCon-OVA and soluble OVA. In contrast to
C57BL/B6 (B6) presentation of peptide from scDEC-OVA could not be seen in DEC205K (DEC/) and TAP knock out (TAP/) mice. On the contrary OVA
peptide from B6 and DEC/ could be presented (C). In (D) to (F) similar data is shown for the spleen. Here as shown in the KO controls presentation was
less efﬁcient in the spleen (F). The experiment was repeated several times with similar results.
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therapeutic or prophylactic vaccines against HIV-1
infection. We have shown in previous reports that
vaccination with aDECmAb-Gag in combination with
polyICLC resulted in strong polyfunctional Gag speciﬁc
CD4þ T cell responses [14, 25, 30, 34]. Similarly, scDEC-Gag
alongside its control scCont-Gag fusion proteins (Supple-
mentary Fig. S1) were expressed puriﬁed and characterized
as previously described [29–31, 33]. To assess the immuno-
genicity of scDEC-Gag plus polyICLC vaccine we immu-
nized C57BL/6 mice twice at 4 weeks interval as previously
reported [14, 25, 30, 36] with the targeted vaccine as well as
the control. Fourteen days after the last vaccination
splenocytes were assessed for Gag speciﬁc T cell responses
by multi-parametric ﬂow cytometry as previously described
[24, 25, 29–31]. As shown in Figure 4 relative to the control
vaccine scDEC-Gag plus polyICLC vaccine (compare
Fig. 4B rows III and IV) induced signiﬁcantly higher Gag
speciﬁc CD4þ T cells immune responses (P< 0.05) which
were seven fold stronger than the control group. This
response was DEC205 dependent as a similar in DEC205
knock out mice (DKO) showed no gag speciﬁc immune
responses.The targeted vaccine also resulted in superior
numbers of single CD4þ T cells simultaneously expressing
multiple cytokines including IL-2, IFN-g, and TNF-a.
Figure 2. Antigen presentation to OT-II T cells following scDEC targeting in vivo.scDEC-OVA induces stronger in vivo proliferation of OT-I I T cells than
OVA alone. C57BL/B6 mice were injected intravenously with 3 106 CFSE-labelled OT-II T-cells then graded doses of scDEC-OVA (A) or OVA (B)
subcutaneously 24 h later. Three days after scDEC injection, draining lymph node cells were harvested and the expansion of CD4þ Va2/20.1 evaluated by
ﬂow cytometry for CFSE dilution. scDEC-OVA elicited better presentation of OVA derived peptide than the scCont-OVA and soluble OVA in both the
lymph node (B) and spleen (E). On the other hand presentaion was abrogated in DEC/mice in both the lymph nodes and spleen (compare C and F). In
contrast to Figure 2 OT-II presentation of peptide from scDEC-OVA could be seen in both TAP knock out (TAP/) and B6 mice but not in DEC205
(DEC/). On the contrary OVA peptide form B6 and DEC/mice was well presented. The experiment was repeated several times with similar results.
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Figure 3. Comparison of Antigen presentation to T cells following scDEC-OVA and aDECmAb-OVA targeting in situ. B6 mice were injected
intravenously with 2 106 or 3 106 CFSE-labeled OT-I and OT-II T-cells respectively 24 h prior to the s.c. injection of graded doses of scDEC-OVA and
aDECmAb-OVA as depicted. Three days after protein injection draining lymph nodes cells were harvested and the expansion of CD8þ Va2ß5.1/5.2 (A) or
CD4þ Va2/20.1 (B) T cells evaluated by ﬂow cytometry. B6 mice were injected s.c with 5 ug of scDEC-OVA or aDECmAb-OVA or the isotype control and
then evaluated for peptide presentation 1, 7, or 15 days later. Treated mice were injected intravenously with 2 106 or 3 106 CFSE-labeled OT-I and
OT-II T-cells respectively. Three days later draining lymph nodes cells were harvested and the expansion of CD8þ Va2ß5.1/5.2 (C) or CD4
þ Va2/20.1 (D) T
cells evaluated by ﬂow cytometry. For mice targeted with scDEC-OVA presentation to OT-I T cells persisted for up 7 days as compared to 15 days for
aDECmAb-OVA targeted mice (A). Similar data for the expansion of OT-1 T cells in the spleen is shown in (E) for scDEC-OVA and (F) for aDECmAb-OVA.
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Figure 4. scDEC-Gag plus polyICLC vaccination results to robust polyfunctional CD4þ T cell responses. C57BL/6 mice were immunized twice s.c. at 4
weeks interval as indicated on the Y-axis 14 after the last vaccination bulk splenocytes were assessed for HIV Gag speciﬁc T cell immunity. Splenocytes
were restimulated either with unreactive peptides or with an HIV Gag p24 peptidemix then IFN-g, IL-2, and TNF-a production in response to peptidewas
evaluated by intracellular cytokine staining 6 h later in T cell (B). In Figure 4A data is shown for the gating schema of the cytokine forming cells while in (B)
is dot plot is shown for IFN-g production by CD4þ T cells in both wild type B6 and DEC205KO mice. Polyfunctional Gag speciﬁc CD4þ T cell responses
14 days after the last boost in DKO mice (C) or wildtype C57BL/6 mice (D). All data are mean SD of three repeat experiments involving ﬁve female
C57BL/6 mice per group.
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In three repeat experiments scDEC-Gag plus polyICLC
resulted in superior polyfunctional CD4þ T cells which were
signiﬁcantly higher than the scCont-Gag (P< 0.001)
(Fig. 4C). When DKO mice were similarly vaccinated little
or no Gag speciﬁc CD4þ T cells were induced clearly
indicating that DEC-205 targeting was implicated in the
enhanced immunogenicity of the targeted vaccine (compare
Fig. 4C with D). Supplementary Figure S3 shows data for
DEC205 expression in the vaccinated mice. These data show
that in the absence of DEC205 there was no difference in the
immunogenicity of scDEC-Gag and scCont-Gag. Again as
previously reported after vaccination with aDECmAb-Gag
protein plus polyIClC [25, 30] no detectable Gag speciﬁc
CD8þ T cells were observed following a similar treatment
with scDEC-Gag protein in combination with polyICLC.
Comparing the immunogenicity of parental
aDECmAb-Gag plus polyICLC with scDEC-Gag
plus polyICLC
As at least 100 ng of scDEC-OVA was needed to produce the
same effect like aDECmAb-OVA we immunize C57BL/6
mice with graded doses of the HIV gag fusion protein
vaccines as indicated the X-axis of Figure 5A–C). Each dose
of vaccine was given with 50mg of plyICLC as described in
materials and methods. Four weeks after priming the mice
received a second dose of the same treatment. Seven days
later HIV gag speciﬁc T cells response are determined as
described above. In Figure 5 data is shown for the mean
percentage cytokine production by CD4 T cells following in
vitro restimulation with HIV gag P24 restrictive peptides.
There was no signiﬁcant difference in the mean percentage
cytokine production for both vaccines after vaccination with
0.1 and 1mg protein (compare Fig. 5A–C). However
following vaccination with 10mg protein; aDECmAb-Gag
protein in combination with polyICLC induce slightly
higher but not signiﬁcant levels (Student’s t test) of IFNg
(Fig. 5A, P< 0.32), Il-2 (Fig. 5B, P< 0.09), and TNF-a
(Fig. 5C, P< 0.14). Thus with respect to immunogenicity
both vaccines induced similar T cell responsesin mice
after s.c. immunization.
scDEC-Gag plus polyICLC vaccination elicits
protection at a mucosal surface
Twelve weeks following vaccination C57BL/B6 mice were
challenged intranasally with recombinant vaccinia-gag as
previously described [9, 11, 12, 24, 25, 30, 31, 35]. In Figure 6
data is shown for three long term repeat experiments.
Control mice vaccinated with the empty scDEC were not
protected relative to PBS-injected mice, and they lost weight
continuously during the challenge. Similarly DKO mice
vaccinated and challenged as described above were not
protected against weight loss (compare Fig. 6A and B).When
virus titers in the lungs were assessed at day 6 post challenge
scDEc-Gag plus polyICLC vaccinated mice show up to 2.5
logs less viruses than the na€ve mice. This lung virus titer was
Figure 5. Comparing the immunogenicity of parental aDECmAb-Gag
plus polyICLCwith scDEC-Gag plus polyICLC. Groups of ﬁve female 6–10
weeks C57BL/6 mice vaccinated twice 4 weeks apart either with graded
doses of scDEC-Gag or aDECmAb-Gag in combination with 50mg polyIC
as indicated on the X-axis. T cells responses were monitored 1 week after
the boost. (A) mean percentage IFNg producing CD4þ T cells (P¼ 0.32;
t-test). (B) as in (A) but shows IL-2 production (P¼ 0.09; t-test). (C) as in
(A) but showing TNF-a producing CD4 T cells 7 days post boost
(P¼ 0.14; t-test). Data represents mean SD of 3 three repeat
experiments with ﬁve mice per group per experiment.
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signiﬁcantly less than mice (P< 0.05) vaccinated with
scCont-Gag plus polyICLC (compare Fig. 6C and D). On
the other hand, similarly vaccinated and challenged DKO
showed signiﬁcantly higher lung virus titer (P< 0.05) in all
groups clearly indicating the relevance of the DEC205
receptor in the targeted vaccination. Thus targeting protein
using scDEC enables the induction of protective T cell
immunity in the airway.
Discussion
We showed that scDEC fusion protein is a simple method of
targeting antigen to DC, leading to presentation both by the
MHC I and II pathway. DEC205 targeting allows for selective
loading of Ag untoDCwhich has been demonstrated to be the
most potent APC, thus representing a useful strategy for
increasing Ag presentation via both the MHC class I and II.
We previously demonstrated that both viral vectored and
DNA vaccines targeting the encoded antigen to DC in vivo
improved T cell responses to gag [29–32]. Here we
demonstrate the efﬁcacy of scDEC-fusion protein in
improvingHIV gag speciﬁc CD4þ T cell immunity inmurine
airwar through selective antigen targeting to dendritic cells in
vivo, in combination with polyICLC as adjuvant.
The potential therapeutic use of scDEC fusion proteins
has several advantages. The variable regions of antibodies
comprise the smallest fragments containing a complete
antibody binding site, and fusion molecules can be created
without loss in binding function [29, 33–35, 37].
Therefore, scDEC is an attractive tool for targeting whole
protein Ag to DC in vivo. The fusion protein scDEC-OVA
and scDEC-Gag with the small molecular size of the scDEC
(38kda) is expected to be minimally immunogenic
permitting repeated immunization without inducing
deleterious anti-host antibody responses. It can be
produced in large amounts, in a short time and at a low
cost, and it can be highly puriﬁed by immobilized metal
afﬁnity chromatography (IMAC), thus providing an ideal
situation for large scale production.
Although the scDEC-OVA as shown here was compara-
ble to the aDECmAb-antigen conjugate only at concen-
trations greater than 100 ng, it was approximately 500 fold
more effective than soluble OVA. The requirement for
large amounts of scDEC fusion proteins may not be a
Figure 6. Dendritic cell targeted scDEC-Gag protein vaccine results to protection in the airway. Groups of ﬁve female 6–10 weeks C57BL/6 mice
vaccinated twice with 5mg scDEC-Gag with 50mg polyIC as adjuvant 4 weeks apart. Twelve weeks after the boost, the mice received a lethal dose
(105 PFU) of recombinant vaccinia-gag intranasally.Weight losswasmonitored daily for 6 days after challenge for (A) DEC205KOor (B) wild type B6mice,
and vaccinia virus titres in the lung (PFU/lung) was measured after euthanizing at 6 days for (C) DEC205KO or (D)WTB6 mice. (mean SD of three
experiments).
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limitation for the induction effective immunity as a
combination of scDEC-Gag plus polyICLC resulted to
similar CD4þ T cell responses like the parental antibody.
As previously reported with the parental aDECmAb-Gag
conjugate scDEC-gag resulted exclusively to CD4þ T cell
responses which were qualitatively and quantitatively
better than non-targeted vaccination [9, 24, 25, 30, 34].
Like previously reported by our group polyfuntional Gag
speciﬁc CD4þ T cells were induced in a DEC205 dependent
manner [30].
In summary, scDEC-OVA and scDEC-Gag fusion
proteins have been developed that targets not only OVA
effectively to CD11cþ cells (Supplementary Fig. S2) but
also induced protective HIV speciﬁc T cell responses in the
airway. This recombinant scDEC fusion protein efﬁciently
targets DC both in vitro and in vivo thereby offering a
simple approach for loading homogeneous Ag onto DC in
vivo. Immunogenicity studies with a model HIV T cell
vaccine also show that the scDEC-Gag administered with
polyICLC as an adjuvant enables protective HIV Gag
speciﬁc T cells responses in the murine airway. Previous
reports from our group had shown that this airway
protection to recombinant vaccinia-gag virus challenge
was mediated by proliferative broad spectrum Gag speciﬁc
CD4þ T cells responses [25, 30] following aDECmAb-Gag
vaccination. The induction of mucosal protective CD4þ T
cells is particularly attractive to combat a challenging virus
like HIV-1 at its portal of entry [37]. However there
remains the also concern that activated CD4þ T cells at the
portal of entry could present new targets for HIV-1
infection. This may not be the case because we previously
demonstrated that these CD4þ T cells would rather help
the rapid induction of pathogen speciﬁc CD8þ T cells [26],
thus this strategy can be exploited in combination with
other vaccination approached to focus pathogen speciﬁc
immune responses at the portal of entry.
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Figure S1. Coomassie stain and FACS analysis of scDEC-
OVA/scDEC-Gag binding to CHOmDEC205 expressing
cells.
Figure S2. scDEC-OVA targeted DCs processed and present
antigen both in vitro and in vivo.
Figure S3. DEC205 expression in WT B6 mice and KOmice
immunized with scDEC-Gag plus polylCLC.
Figure S4. Durable HIV Gag speciﬁc CD4 T cell cytokine
production after scDEC-Gag plus polylCLC vaccination.
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